This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Discover why dividend ETFs incur fees, including management costs and tracking errors, and how those charges influence your long-term results.
26,393 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Discover what the (sfl) 2026 earnings call implies for revenue trends, balance sheet health, and the road ahead. This...
A surge in AI workloads hinges on memory, and Micron’s latest signals hint at lasting strength. This piece unpacks wh...
Beasley (BBGI) has a unique mix of local radio and digital assets. This guide breaks down what to watch in the 2025 e...
As we reach the halfway point of 2026, certain S&P 500 members are leading the pack with impressive gains. This artic...
As shipping cycles turn, Safe Bulkers faces a critical earnings season. This guide deconstructs the Q4 2025 call, hig...
Microsoft stock is moving higher in a volatile market, defying a tech sell-off. This article breaks down the drivers ...
AI momentum is powering a three-way race among AMD, Nvidia, and Broadcom. This guide breaks down who offers the best ...
This guide breaks down what to watch in Jackson Financial's 2025 earnings, with practical tips and real-world scenari...
Nvidia and Micron are central to AI data centers, but one may be the better buy for your portfolio. This guide breaks...
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
As DNOW readies its 2025 earnings narrative, investors should focus on backlog, free cash flow, and guidance. This gu...